QUIA PHARMA AB (FRA:99B0) Total Liabilities: €0.80 Mil (As of Jun. 2025)


What is QUIA PHARMA AB Total Liabilities?

QUIA PHARMA AB FRA:99B0 Total Liabilities is €0.80 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

QUIA PHARMA AB's Total Liabilities for the quarter that ended in Jun. 2025 was €0.80 Mil.

QUIA PHARMA AB's quarterly Total Liabilities declined from Jun. 2024 (€0.70 Mil) to Dec. 2024 (€0.56 Mil) but then increased from Dec. 2024 (€0.56 Mil) to Jun. 2025 (€0.80 Mil).

QUIA PHARMA AB's annual Total Liabilities increased from Dec. 2022 (€1.91 Mil) to Dec. 2023 (€2.39 Mil) but then declined from Dec. 2023 (€2.39 Mil) to Dec. 2024 (€0.56 Mil).

QUIA PHARMA AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for QUIA PHARMA AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

QUIA PHARMA AB Total Liabilities Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 2.31 1.91 2.39 0.56

QUIA PHARMA AB Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 2.39 0.70 0.56 0.80

QUIA PHARMA AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

QUIA PHARMA AB's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.556+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.56

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=1.591-1.035
=0.56

QUIA PHARMA AB's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.8+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.80

Total Liabilities=Total Assets (Q: Jun. 2025 )-Total Equity (Q: Jun. 2025 )
=1.387-0.587
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €0.80 Mil mean?
QUIA PHARMA AB (FRA:99B0) has a Total Liabilities of €0.80 Mil as of Jun. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's Total Liabilities too high?
QUIA PHARMA AB's current Total Liabilities is €0.80 Mil.
How does QUIA PHARMA AB's Total Liabilities compare to VRTX and REGN?
QUIA PHARMA AB's Total Liabilities of €0.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current Total Liabilities is €0.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Total Liabilities of €0.80 Mil. The current Total Liabilities is €0.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Total Liabilities is €0.80 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.